medRxiv preprint doi: https://doi.org/10.1101/2024.01.17.24301423; this version posted March 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Clinical Characteristics and Factors Associated with Long COVID in Zambia, August 2020 to January 2023: A Mixed Methods Design

Warren Malambo[1]*, Duncan Chanda[2,3] ,Lily Besa[3], Daniella Engamba[2,3], Linos Mwiinga[1], Mundia Mwitumwa[2], Peter Matibula[2], Neil Naik[2], Suilanji Sivile[2,3], Simon Agolory [1], Andrew Auld[1], Lloyd Mulenga[3], Jonas Z. Hines[1,¶], Sombo Fwoloshi[2,3, ¶]

[1] U.S. Centers for Disease Control and Prevention, Division of Global HIV/TB, Lusaka, Zambia
[2] University Teaching Hospital Adult and Emergency Hospital, Department of Internal Medicine, Lusaka, Zambia
[3] Ministry of Health, Lusaka, Zambia

* Corresponding author:
Email: ykh1@cdc.gov (WM)

¶ These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.17.24301423; this version posted March 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Introduction

A number of seroprevalence studies in Zambia document the extent of spread of SARS-CoV-2, yet few have examined signs, symptoms and conditions that continue or develop after acute COVID-19 infection (long COVID). This is an important gap given the estimated prevalence of long COVID in other countries. We sought to examine characteristics of post-acute COVID-19 (PAC-19) clinics patients in Zambia and assess factors associated with long COVID at first visit to a PAC-19 clinic and longitudinally among a cohort of patients.

Methods

Long COVID was defined, initially in the Zambia PAC-19 clinical guidelines, as new, relapsing, or persistent symptoms lasting >4 weeks after an initial SARS-CoV-2 infection. Severe COVID-19 was defined as COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids/remdesivir. We performed a cross-sectional and longitudinal analysis of PAC-19 clinic patients from August 2020 to January 2023 using logistic and mixed effects regression models and considered statistical significance at $p<0.05$.

Results

In total, 1,359 patients attended PAC-19 clinics of whom 548 (40.3%) with ≥2 visits were included in the longitudinal analysis. Patients' median age was 53 (interquartile range [IQR]: 41-63) years, 919 (67.6%) were hospitalized for acute COVID-19, and of whom 686 (74.6%) had severe COVID-19. Patients with hospital length of stay ≥15 days (adjusted odds ratio [aOR]: 5.37; 95% confidence interval [95% CI]: 2.99-10.0), severe illness (aOR: 3.22; 95% CI: 1.68-6.73), and comorbidities (aOR:1.50; 95% CI: 1.02-2.21) had significantly higher likelihood of long COVID. Longitudinally, long COVID prevalence significantly ($p<0.001$) declined from 75.4% at the first PAC-19 visit to 26.0% by the fifth visit. The median follow-up time was 7 (IQR: 4-12) weeks.

Conclusion

Long COVID symptoms were common among patient presenting for care in PAC-19 clinics in Zambia, but most recovered within ~2 months. Despite potentially substantial morbidity due to long COVID, few patients overall with COVID-19 attended a PAC-19 clinic. Scaling up PAC-19 services and integrating into routine clinical care could improve access by patients.

Introduction

Since the identification of the first SARS-CoV-2 infections in December 2019, the Coronavirus disease 2019 (COVID-19) has become a major public health problem. Its morbidity and mortality dramatically increased across countries and regions leading to its classification as a pandemic [1]. As of February 2024, the World Health Organization (WHO) had reported over 774 million cumulative COVID-19 cases and over 7 million cumulative COVID-19 deaths globally [2]. In the Africa region alone, over 9.5 million cumulative COVID-19 cases and over 175 thousand COVID-19 deaths were reported for the same time period.

People infected with SARS-CoV-2 commonly develop symptoms within 4-5 days following exposure although others may be asymptomatic [3]. Acute COVID-19 (within 4 weeks from the initial SARS-CoV-2 infection) presents with as a multi-system cluster of symptoms, i.e., general, cardiovascular, pulmonary, gastrointestinal, neurologic, musculoskeletal, and ear, nose, and throat. Recovery from COVID-19 for most patients occurs within 7-10 days after symptoms onset but could take weeks to months in some patients [4-7]. Previous epidemics such the 2003 severe acute respiratory syndrome (SARS) and the 2012 Saudi Arabia Middle East respiratory syndrome coronavirus (MERS-CoV) had patients who presented with persistent symptoms post-acute infection [8-11]. Their symptoms included fatigue, decreased quality of life, shortness of breath and behavior health problems that impacted on their health-related quality of life.

Symptoms and conditions that continue or develop after acute COVID-19 infection are variably named (post-acute COVID-19, post-acute sequelae of SARS-CoV-2 infection, post-COVID conditions, long-haul COVID, post-COVID conditions, long-term effects of COVID and chronic COVID) but are also referred to as long COVID [6, 12]. Commonly reported long COVID symptoms include fatigue, fever, cough, dizziness, brain fog, and myalgia although symptoms are varied and potentially have overlapping etiologies [13-15]. Long COVID is thus a syndrome characterized by persistent, new, relapsing or delayed SAR-CoV-2 symptoms ≥12 weeks beyond onset of the acute episode [12, 16-18], and can have a protracted path to recovery that impacts on quality of life, earnings and health care costs [19-21].

As much as 77 million people around the world could be estimated to have long COVID, based on a conservative estimated prevalence of 10% of reported number of infected people [2, 22]; the actual number may likely be much higher given undocumented cases due to limited testing capacity. Among acute-COVID-19 outpatient cases, the prevalence of long COVID is estimated at 10-30%; 50-70% of hospitalized cases and 10-12% of vaccinated cases [22-27]. For example, a study of the burden,

79 causation, and particularities of long COVID in 7 African countries estimated a pooled long COVID
80 prevalence of 41% [28]. Long COVID is associated with increasing age, comorbidities, hospitalization for
81 acute COVID-19, severe COVID-19, and vaccination status [29-31]. Vaccination against SARS-CoV-2 is,
82 however, associated with reduced likelihood of severe COVID-19 and long COVID.

83 There's growing evidence on long COVID from countries in Africa [28, 32-34]. Disease severity and
84 admission to the intensive care unit during acute COVID-19, for example, were found to be associated
85 with long COVID in Nigeria and South Africa [35, 36]. Scoping studies on long COVID in Africa found
86 comorbidities and age >40 years to be associated factors [33, 37]. In Zambia, 17% of persons with acute
87 COVID-19 in July 2020 were found to be experiencing symptoms ~2 months later [38]. Zambia's reported
88 COVID-19 cases are, however, likely an underestimate given limited testing capacity, asymptomatic
89 infections, and mild clinically ill cases who may not have come to the attention of the health system [39-
90 41].

91 While a number of seroprevalence studies in Zambia document the extent of spread of SARS-CoV-2, few
92 have examined longer term outcomes such as long COVID [36, 39, 41-45]. This is an important gap given
93 the estimated prevalence of long COVID and extent of SARS-CoV-2 transmission in other countries in
94 Africa. In this study, we examined the characteristics of patients presenting for care in specialized post-
95 acute COVID-19 (PAC-19) clinics in Zambia and assessed factors associated with long COVID at first visit
96 to a PAC-19 clinic and longitudinally among a cohort of patients with ≥2 PAC-19 clinic visits.

97 Methods

98 Study setting

99 Beginning August 2020, the Zambia Ministry of Health set up 13 specialized PAC-19 clinics to care for
100 people following SARS-CoV-2 infection, initially at the two national referral hospitals in Lusaka city, the
101 capital of Zambia, and subsequently at 11 other major hospitals across all 10 provinces of Zambia.

102 Study participants

103 Per national PAC-19 clinical guidelines, patients diagnosed with SARS-CoV-2 infection presented in PAC-
104 19 clinics for follow-up care after discharge from hospital admission or outpatient episodic [46]. At the
105 first PAC-19 clinic visit, patients' demographics, medical history, comorbidities, and current symptoms
106 were recorded on a standardized paper form. Physical examinations and laboratory investigations were
107 conducted based on patient's medical history as required. Patients' ability to perform activities, as part
108 of examination of their functional and mental health status, were also evaluated.

109 Further clinical appointments of up to 5 review visits were at the clinicians' discretion. Symptoms were
110 assessed by clinicians at each PAC-19 clinic visit on review of systems: general, cardiovascular,
111 pulmonary, urinary, neurologic, musculoskeletal, ear, nose, and throat (ENT), mental health concerns,
112 depression, anxiety, and dermatologic. Pre-existing comorbidities (hypertension, diabetes,
113 cardiovascular disease, cancer, chronic lung disease, kidney disease, or liver disease,
114 immunosuppression, obesity, HIV and TB) were documented. Patients requiring further specialist care
115 were referred to various units including physiotherapy, cardiology, endocrinology, nephrology,
116 psychiatry, and pulmonology. Anonymized data from patients standardized clinical paper forms were
117 routinely abstracted into an electronic database (REDCap v11.0.3); which was accessed on 5th January
118 2023 and analyzed for this study.

119 **Study design**

120 We implemented a mixed methods design to assess for factors associated with long COVID at first visit
121 to a PAC-19 clinic and longitudinally across review visits. First, we performed a cross-sectional analysis of
122 all PAC-19 clinic patients with data entered in the REDCap electronic databases from August 5, 2020,
123 through to January 26, 2023. We then did a longitudinal sub-analysis of patients with ≥2 PAC-19 clinic
124 review visits.

125 The longitudinal sub-analysis data structure included repeated observations of long COVID symptoms
126 and patient-level characteristics. Demographic and clinical characteristics of patients included time-
127 invariant covariates sex, age (patients repeatedly observed for <1 year), presence of newly diagnosed
128 medical conditions, presence of pre-existing comorbidities, and acute COVID-19 episode details. Time-
129 variant covariates included COVID-19 vaccination status and referral to specialist services.

130 **Study variables and definitions**

131 Long COVID was defined, initially in the Zambia post-acute COVID-19 guidelines, as new, relapsing or
132 persistent COVID-19 symptoms that lasted greater than 4 weeks after the initial SARS-CoV-2 infection
133 [46, 47]. Severe COVID-19 was defined as COVID-19 episode that required supplemental oxygen
134 therapy, intensive care unit (ICU) stay or treatment with steroids or remdesivir. Vaccination status
135 categorization was based on vaccination records, when available, or patients' self-reported status. SARS
136 CoV-2 variants classification was based on the dominant variant at the time of SARS-CoV-2 diagnosis as
137 captured by the Zambia's genomic surveillance system and submitted to the Global Initiative on Sharing
138 All Influenza Data (GISAID) rather than sequenced specimens from patients [48]. Diabetes, hypertension,

139 or deep vein thrombosis/pulmonary embolism detected at the time of SARS-CoV-2 diagnosis were
140 categorized as newly diagnosed medical conditions.

141 **Study size**

142 For the study sample size, we assumed prevalence of long COVID at 30% and a precision corresponding
143 to the effect size of 5%. The prevalence or Cochrane formula (described elsewhere) was used to
144 calculate the minimum sample size of 323 [49]. Study participants were included in the study if they
145 were COVID-19 patients presenting in PAC-19 clinics for follow-up care after discharge from hospital or
146 outpatient episodic care and had their information abstracted to the clinics' REDCap electronic
147 database. A full enumeration of all PAC-19 clinic attendees was however considered for higher accuracy
148 and precision. For the longitudinal sub-analysis, patients were excluded from the analysis if they
149 attended a PAC-19 clinic only once.

150 **Statistical Analysis**

151 At descriptive statistics we reported frequencies with proportions for categorical variables and medians
152 with the interquartile range (IQR) for non-normally distributed numeric variables assessed using the
153 Shapiro-Wilk test. The Pearson Chi-square and Kruskal Wallis tests for proportions and Wilcoxon rank
154 sum test for medians were used to estimate the direction and magnitude of association. An unadjusted
155 and adjusted logistic regression model was fitted to assess for factors associated with having long COVID
156 at first visit to a PAC-19 clinic.

157 The main cross-sectional analysis was for patients hospitalized during acute COVID-19 (inpatients) to
158 maintain key variables in the analysis. At multivariable analysis, we adjusted for age, presence of newly
159 diagnosed medical conditions, presence of pre-existing comorbidities, and COVID-19 episode details
160 (i.e., hospital length of stay, and presence of severe COVID-19). Covariate inclusion criteria at
161 multivariable analysis were based on theoretical relevance to the study and statistical significance (p-
162 value≤0.2). We also conducted an additional cross-sectional analysis that included both inpatients and
163 outpatients during acute infection to assess for association of hospitalization during acute COVID-19
164 with long COVID.

165 For the longitudinal sub-analysis, we a fitted mixed effects model to account for the heterogeneity in
166 long COVID i.e., the differences between patients and within patients across repeated observations or
167 PAC-19 clinic visits. An unadjusted and adjusted mixed effects model was separately fitted for acute
168 COVID-19 inpatients only and additionally for both inpatients and outpatients. The patient was the
169 random effects term for the model. Since there was dependence in the data, we also reported the

170 conditional intraclass correlation (ICC) which quantified the variance in long COVID heterogeneity that
171 was attributable to between patients and within patients across PAC-19 visits.

172 Only covariates with <10% missingness were included at multivariable analyses. To assess for bias, we
173 checked for the proportion of listwise deletion when covariates of interest with >10% missingness were
174 included at multivariable analysis. Model selection was based on goodness-of-fit statistics (i.e., adjusted
175 pseudo R^2, Akaike information criteria, Bayesian information criteria and log-likelihood value). Analysis
176 was done in R software version 4.3.2 (R Foundation for Statistical Computing) and statistical significance
177 was considered at $p<0.05$.

178 **Ethical considerations**

179 This study was preconceived during the development of clinical and operational guidelines for the
180 management of PAC-19 patients in Zambia. The study obtained ethical clearance (waiver for informed
181 consent) from the University of Zambia Biomedical Research Ethics Committee (Ref No. 2711-2022),
182 approval from the Zambia National Health Research Authority (Ref No: NHRA0002/26/05/2022) and was
183 determined to be non-research according to the U.S Centers for Disease Control and Prevention (CDC)
184 policy and applicable federal law (See e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C.
185 §241(d); 5 U.S.C. 552a; 44 U.S.C.3501 et seq.). CDC investigators did not interact with patients or have
186 access to personally identifiable information but participated in protocol development and analysis of
187 anonymized data.

188 **Results**

189 In total, 1,359 patients that attended PAC-19 clinics from August 2020 to January 2023 were in the cross
190 sectional analysis (Fig 1). Of these patients, 548 (40.3%) patients that had ≥2 PAC-19 clinic visits were
191 included in the longitudinal sub-analysis. Most patients (919/1,087, 84.5%) were hospitalized during
192 acute COVID-19 (Table 1). Overall, patients' median age was 53 (IQR: 41-63) years, and 693 (52.9%) were
193 female. Most patients (58.0%) were from Lusaka, where the first two PAC-19 clinics were initially set up.
194 Nearly half of the patients (46.9%) were diagnosed with COVID-19 when delta was the dominant variant
195 (Fig. 2). The median time since COVID-19 diagnosis when patients presented for care in PAC-19 clinics
196 was 4 (IQR:2-6) weeks.



Fig 1: Analysis flow diagram of PAC-19 clinic patients in Zambia, August 2020 – January 2023

Table 1: Demographic and Clinical Characteristics of Patients who Presented for Care in PAC-19 Clinics in Zambia, Aug. 2020–Jan. 2023

Characteristic	Presence of long COVID symptoms			p-value [a]
	Yes (377) n (%)	No (982) n (%)	Overall (1,359) n (%)	
Sex				0.994
Female	197 (53.0)	496 (52.9)	693 (52.9)	
Male	175 (47.0)	441 (47.1)	616 (47.1)	
(Missing)	5	45	50	
Age (years)				**0.016**
Median (IQR)	53 (43, 66)	52 (40, 63)	53 (41, 63)	
(Missing)	0	45	45	
Age group (years)				**0.039**
≤29	22 (5.8)	98 (10.5)	120 (9.1)	
30-39	47 (12.5)	132 (14.1)	179 (13.6)	
40-49	84 (22.3)	188 (20.1)	272 (20.7)	
50-59	82 (21.8)	219 (23.4)	301 (22.9)	
60+	142 (37.7)	300 (32.0)	442 (33.6)	
(Missing)	0	45	45	
PAC-19 Clinic location				0.152
Lusaka city	158 (54.5)	433 (59.4)	591 (58.0)	

Characteristic	Presence of long COVID symptoms			p-value [a]
	Yes (377) n (%)	No (982) n (%)	Overall (1,359) n (%)	
Other districts	132 (45.5)	296 (40.6)	428 (42.0)	
(Missing)	87	253	340	
Dominant SARS-CoV-2 variant at diagnosis [b]				**<0.001**
Wild type	17 (4.6)	55 (5.8)	72 (5.4)	
Beta	94 (25.3)	186 (19.5)	280 (21.1)	
Delta	190 (51.1)	433 (45.3)	623 (46.9)	
Omicron	71 (19.1)	282 (29.5)	353 (26.6)	
(Missing)	5	26	31	
Time since COVID-19 diagnosis (weeks) [c]				**<0.001**
Median (IQR)	6 (5, 10)	3.0 (2, 5)	4.0 (2, 6)	
(Missing)	118	251	369	
Presence of pre-existing comorbidities [d]				**<0.001**
No	155 (41.1)	550 (56.0)	705 (51.9)	
Yes	222 (58.9)	432 (44.0)	654 (48.1)	
Presence of newly diagnosed medical conditions [e]				**0.005**
No	331 (87.8)	909 (92.6)	1,240 (91.2)	
Yes	46 (12.2)	73 (7.4)	119 (8.8)	
Vaccination status				0.422
Not vaccinated	250 (78.1)	543 (75.8)	793 (76.5)	
Vaccinated	70 (21.9)	173 (24.2)	243 (23.5)	
(Missing)	57	266	323	
Hospitalization status during acute COVID-19				0.428
Outpatient	45 (14.1)	123 (16.0)	168 (15.5)	
Inpatient	274 (85.9)	645 (84.0)	919 (84.5)	
(Missing)	58	214	272	
Hospitalization length of stay (days) [f]				**<0.001**
1-3	19 (9.4)	139 (26.8)	158 (21.9)	
4-7	38 (18.8)	165 (31.8)	203 (28.2)	
8-14	48 (23.8)	125 (24.1)	173 (24.0)	
≥15	97 (48.0)	90 (17.3)	187 (25.9)	
(Missing)	72	126	198	
Severe COVID [f, g]				**0.001**
No	50 (18.2)	183 (28.4)	233 (25.4)	
Yes	224 (81.8)	462 (71.6)	686 (74.6)	
Functional status since COVID-19				**<0.001**
Better	144 (55.2)	427 (78.8)	571 (71.1)	
Same/worse [h]	117 (44.8)	115 (21.2)	232 (28.9)	
(Missing)	116	440	556	
Referral to specialist services [i]				**0.001**
No	221 (89.1)	614 (95.0)	835 (93.4)	
Yes	27 (10.9)	32 (5.0)	59 (6.6)	
(Missing)	129	336	465	

[a] Pearson Chi-square and Kruskal Wallis tests were used for proportions and Wilcoxon rank sum test for medians. Bolded p-values are significant at $p<0.05$

[b] SARS CoV-2 variants classification based on GISAID (2023) rather than sequenced specimens from study patients

[c] Computed as a difference in weeks between date of diagnosis and date of presentation at PAC-19 clinic

[d] Pre-existing comorbidity: hypertension, diabetes, cardiovascular disease, cancer, immunosuppression, chronic lung, kidney, and liver diseases, obesity, HIV and TB.

[e] Comorbidities (hypertension, diabetes, and HIV) diagnosed at the time of SARS CoV-2 infection.

[f] Denominator is 919 (i.e., patients hospitalized for acute COVID-19)

[g] Acute COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids or remdesivir

[h] Same or worse limitations in daily activities since acute COVID-19

[i] Specialist services included physiotherapy, cardiology, endocrinology, nephrology, psychiatry, and pulmonology



Fig 2: PAC-19 clinic patients' attendance by date of diagnosis, August 2020 – January 2023

At baseline, 654 (48.1%) patients overall, reported having had pre-existing comorbidity. Among these patients, hypertension (n=465, 71.1%), diabetes (n=172, 26.3%), HIV (n=165, 25.2%) and cardiovascular disease (n=73, 11.2%) were commonly (frequency of ≥10%) reported (S1 Table). One hundred nineteen (8.8%) patients had been diagnosed with new medical conditions at the time of SARS-CoV-2 diagnosis. Of these patients, hypertension and diabetes were detected at SARS-CoV-2 diagnosis in 68 (53.8%) and 64 (53.8%) patients, respectively.

Among the hospitalized acute COVID-19 patients, the median length of stay was 7 days (IQR:4-15 days). Of these inpatients, 686 (74.6%) were categorized as having had severe COVID-19. The medium time from the date of COVID-19 diagnosis to when patients presented for care in a PAC-19 clinic was 4 weeks (IQR: 2-6 weeks). At first visit to a PAC-19 clinic, 274 (29.8%) hospitalized patients had long COVID. Among these long COVID patients, commonly reported symptoms included cough (38.7%), fatigue (38.5%), shortness of breath (26.5%), chest pain (20.9%), headache (14.8%), muscles aches/pain (14.1%), palpitations (12.5%), joint aches/pain (11.9%), and forgetfulness or brain fog (8.0%). Among the outpatients, 103 (23.4%) had long COVID, bringing the overall number of long COVID patients to 377 (27.7%).

222 Of all patients, 232 (28.9%) patients had worse or same (limitations in daily activities) functional status
223 since acute COVID-19. The functional status patients commonly reported difficulty in undertaking was
224 walking long distances greater than 1km (22.6%), day-to-day work/school (cognitive) activities (19.4%),
225 standing for ≥30 minutes (19.4%), taking care of household tasks (17.8%), and self-care (activities like
226 bathing and dressing) – 15.1%. Fifty-nine (6.6%) patients were referred to specialist care, including
227 cardiology (35.6%), endocrinology (33.9%), psychiatry (25.4%), pulmonology (18.6%), physiotherapy
228 (11.0%), and nephrology (1.7%).

229 Overall, 243 (23.5%) patients had been vaccinated before being diagnosed with SARS-CoV-2,
230 representing 28.5% of patients seen at PAC-19 clinics from April 2021 when COVID-19 vaccines first
231 became available in Zambia. Of these vaccinated patients, 102 (42%%) received Johnson and Johnson's
232 Janssen (Ad26.COV2.S), 97 (39.9%%) received AstraZeneca (AZD1222), 41 (16.9%%) did not know the
233 vaccine type they received, and 3 (1.2%%) received Pfizer-BioNTech (BNT162b2). Fifty-seven (23.4%) had
234 received a full series of vaccines >14 days prior to their date of SARS-CoV-2 diagnosis, 31 (12.7%) were
235 partially vaccinated (i.e., 2nd dose not yet received), 10 (4.1%) were diagnosed with SARS-CoV-2 within
236 14 days of being vaccinations while 148 (60.9%) had missing vaccination dates to be classified.

237 Patients with pre-existing comorbidities (adjusted odds ratio [aOR]: 1.50; 95% confidence interval [CI]:
238 1.02-2.21), and with hospital length of stay of 8-14 and ≥15 days were associated with significantly
239 higher odds of long COVID (aOR: 1.98; CI: 95% 1.08-3.74, and aOR: 5.37; 95% CI: 2.99-10.0, respectively)
240 - Table 2. Patients who had severe COVID-19 had 3.23-fold (95% CI: 1.68-6.75) higher odds of presenting
241 with long COVID. Independently, vaccinated patients had non-significant reduced likelihood of long
242 COVID (OR: 0.94; 95% CI: 0.64-1.36) while those who were referred to specialist services had 1.88-fold
243 (95% CI: 1.00-3.48; p-value=0.045) increased likelihood of long COVID.

244 **Table 2**: Factors associated with long COVID at first visit to PAC-19 clinic among patients hospitalized for
245 acute COVID-19 in Zambia, August 2020 – January 2023 (N=919)

Variable	Unadjusted OR (95% CI)	p-value [a]	Adjusted OR (95% CI)	p-value [a]
Sex				
Female	*Referent*	-	Referent	-
Male	0.98 (0.74, 1.31)	0.912	0.92 (0.65-1.32)	0.667
Age group (years)				
≤29	*Referent*	-	*Referent*	-
30-39	1.73 (0.88, 3.51)	0.116	0.87 (0.38, 2.01)	0.741
40-49	2.01 (1.09, 3.87)	**0.029**	0.82 (0.39, 1.76)	0.596
50-59	1.69 (0.93, 3.24)	0.096	0.70 (0.33, 1.51)	0.350
60+	1.86 (1.05, 3.47)	**0.041**	0.61 (0.30, 1.28)	0.181

Variable	Unadjusted OR (95% CI)	p-value [a]	Adjusted OR (95% CI)	p-value [a]
Presence of pre-existing comorbidities [b]				
No	*Referent*		*Referent*	-
Yes	1.50 (1.12, 2.01)	**0.006**	1.50 (1.02, 2.21)	**0.041**
Presence of newly diagnosed medical conditions [c]				
No	*Referent*	-	*Referent*	-
Yes	1.48 (0.94, 2.30)	0.084	1.34 (0.78, 2.28)	0.284
Hospital length of stay (days)				
1-3	*Referent*	-	*Referent*	-
4-7	1.68 (0.94, 3.11)	0.086	1.26 (0.68, 2.39)	0.478
8-14	2.81 (1.59, 5.14)	**<0.001**	1.98 (1.08, 3.74)	**0.031**
≥15	7.88 (4.60, 14.1)	**<0.001**	5.37 (2.99, 10.0)	**<0.001**
Severe COVID-19 [d]				
No	*Referent*		*Referent*	-
Yes	1.77 (1.26, 2.54)	**0.001**	3.22 (1.68, 6.73)	**<0.001**
Vaccination status [e]				
Not vaccinated	*Referent*		-	-
Vaccinated	0.94 (0.64, 1.36)	0.737	-	-
Referral to specialist services [e]				
No	*Referent*		-	-
Yes	1.88 (1.00, 3.48)	**0.045**	-	-

Abbreviation: OR - odds ratio; CI – confidence interval

[a] Bolded p-values are significant at p<0.05

[b] Pre-existing comorbidity: hypertension, diabetes, cardiovascular disease, cancer, immunosuppression, chronic lung, kidney, and liver diseases, obesity, HIV and TB.

[c] Comorbidities (hypertension, diabetes, and HIV) diagnosed at the time of SARS CoV-2 infection.

[d] Acute COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids/ remdesivir

[e] Vaccination status and referral to specialist services were not adjusted for at multivariable analysis due to >10% missingness which resulted in 50.5% listwise deletion.

246

247 In the additional cross-sectional analysis that included both inpatients and outpatients during acute
248 COVID-19 (S2 Table), inpatients were associated with non-significant increased odds of long COVID (aOR:
249 1.05; 95% CI: 0.72-1.55). Patients with the presence of comorbidities were, however, associated with
250 significantly higher odds of long COVID (aOR: 1.55; 95% CI: 1.16-2.08) while the presence of newly
251 diagnosed medical conditions had a non-significant increase likelihood of long COVID. Patients aged 40-
252 49 years were significantly associated with 1.79-fold increased likelihood of long COVID (95% CI: 1.03-
253 3.22). Independently, patients referred to specialist services were 2.34 times (95% CI: 1.37-4.00) more
254 likely to present with long COVID. Males compared to females and having been vaccinated against
255 COVID-19 were associated with non-significant reduced odds of long COVID.

256 In the longitudinal analysis (S1 Fig), the overall median time patients presented at a PAC-19 clinic was 7
257 (IQR: 4-12) weeks. Longitudinally (Fig 3), the most frequently (≥5% at any PAC-19 clinic visit) reported

258 long COVID symptoms were cough (16.9%), fatigue (16.4%), shortness of breath (10.6%), chest pain
259 (8.4%), headache (8.3%), palpitations (6.6%) and muscle aches/pains (5.2%), and forgetfulness (3.0%).
260 The prevalence of long COVID significantly declined (p<0.001) from 75.4% at the first PAC-19 clinic visit
261 to 53.5% at the second visit, 59.8% at the third visit, 49.6% at the fourth visit, and 26.0% at the final visit
262 (S3 Table). Overall, the proportion of vaccinated patients attending PAC-19 clinics increased from 20% at
263 the first visit to 58% at the fifth visit; an increase that will statistically significant (p<0.001). Similarly,
264 comparatively significantly (p=0.002) larger proportion of patients with comorbidities presented in
265 subsequent PAC-19 clinic visits than at the first visit. The proportion of patients with newly diagnosed
266 medical conditions longitudinally declined; this was, however, non-significant (p=0.953).



267
268 **Fig 3**: Longitudinal frequency of most common long COVID symptoms by PAC-19 clinic visit, Aug. 2020 -
269 Jan. 2023

270

271 We found similar associations with long COVID in the longitudinal analysis (Table 3) as with the cross-
272 sectional analysis (Table 2). Across subsequent clinical visits, the odds of long COVID declined overall.
273 Patients with hospital length of stay of ≥15 days and those with severe COVID-19 had significantly
274 increased likelihood of presenting with long COVID (aOR: 4.30; 95% CI: 1.54-12.0, and aOR: 1.89; 95% CI:
275 1.02-3.49, respectively). Longitudinally, vaccinated patients had a non-significant reduced odds of long
276 COVID (aOR: 0.78; 95% CI: 0.45-1.35). Similarly, sex, age, presence of comorbidities and newly diagnosed
277 medical conditions were associated with non-significant likelihood of long COVID. For the longitudinal
278 model, the conditional ICC was estimated to be 0.562; suggesting that 56.2% of the longitudinal variance
279 in long COVID was attributable to between patient differences.

280

281

282 **Table 3:** Factors longitudinally association with long COVID among acute COVID-19 hospitalized patients in
283 Zambia, August 2020 – January 2023 (N=540)

Variable	Adjusted model [a]		Fully adjusted model [b]	
	aOR (95% CI)	p-value [c]	aOR (95% CI)	p-value [c]
PAC-19 clinic visit				
1	Referent	-	Referent	-
2	0.18 (0.12, 0.27)	**<0.001**	0.18 (0.11, 0.31)	**<0.001**
3	0.09 (0.04, 0.18)	**<0.001**	0.09 (0.04, 0.21)	**<0.001**
4	0.02 (0.01, 0.06)	**<0.001**	0.02 (0.01, 0.06)	**<0.001**
5	0.00 (0.00, 0.01)	**<0.001**	0.00 (0.00, 0.02)	**<0.001**
Sex				
Female	Referent	-	Referent	-
Male	0.81 (0.52, 1.27)	0.367	0.75 (0.42, 1.36)	0.348
Age group (years)				
≤29	Referent	-	Referent	-
30-39	2.25 (0.64 , 7.94)	0.208	1.07 (0.19, 6.09)	0.937
40-49	1.60 (0.51, 5.02)	0.422	0.68 (0.14, 3.26)	0.634
50-59	1.56 (0.51, 4.81)	0.438	0.79 (0.17, 3.75)	0.765
60+	2.56 (0.85 , 7.67)	0.094	1.27 (0.27, 5.84)	0.762
Presence of newly diagnosed medical conditions				
No	Referent	-	Referent	-
Yes	1.55 (0.76, 3.14)	0.227	1.41 (0.58, 3.43)	0.449
Presence of comorbidities				
No	Referent	-	Referent	-
Yes	1.86 (1.18, 2.92)	**0.007**	1.66 (0.88, 3.14)	0.117
Hospital length of stay (days)				
1-3	Referent	-	Referent	-
4-7	1.95 (0.72 , 5.25)	0.187	1.73 (0.65, 4.61)	0.271
8-14	2.18 (0.80 , 5.90)	0.127	1.74 (0.64, 4.71)	0.277
≥15	5.92 (2.14 , 16.42)	**0.001**	4.30 (1.54, 12.0)	**0.005**
Severe COVID-19 [d]				
No	Referent	-	Referent	-
Yes	1.44 (0.90, 2.31)	0.124	1.89 (1.02, 3.49)	**0.042**
Vaccination status				
Not vaccinated	Referent	-	Referent	-
Vaccinated	0.79 (0.50, 1.26)	0.326	0.78 (0.45, 1.35)	0.380
Referral to specialist Services [e]				
No	Referent	-	-	-
Yes	1.01 (0.53, 1.95)	0.973	-	-
Random Effects				
Between PAC-19 clinic visit variance			3.29	
Within PAC-19 clinic visit variance			4.22	
Conditional intraclass correlation			0.56	

[a] Models adjusted for fixed effects term PAC-19 clinic visit occasion.

[b] Fully adjusted model included measurement occasion fixed effects term (PAC-19 clinic visit occasions) and patient level fixed effects terms: age (<29, 30-39, 40-49, 50-59, or +60 years), presence of comorbidities (yes or no), presence of newly diagnosed comorbidity (yes or no),

Variable	Adjusted model [a]		Fully adjusted model [b]	
	aOR (95% CI)	p-value [c]	aOR (95% CI)	p-value [c]

acute COVID-19 hospitalization length of stay (1-3, 4-7, 8-14, and ≥15 days), severe COVID-19 during acute COVID-19 (yes or no), and COVID-19 vaccination status (not vaccinated or vaccinated). The random-effects term for longitudinal clustering of repeated measure was the patient.

[c] Bolded p-values are significant at p<0.05

[d] Acute COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids/remdesivir

[e] Referral to specialist services not adjusted for at multivariable analysis due to 32.6% missingness which resulted in 57.9% listwise deletion.

284

285 In the longitudinal sub-analysis that included both those that were inpatients and outpatients during
286 acute COVID-19 (S4 Table), similar associations were observed as to the cross section sub-analysis (S2
287 Table). The likelihood of presenting with long COVID significantly (p<0.001) declined, overall, across
288 subsequent PAC-19 clinic visits (S4 Table). The presence of comorbidities were longitudinally associated
289 with increased odds of long COVID by a factor of 1.67 (95% CI: 1.02-2.75). Hospitalized patients during
290 acute COVID-19, vaccinated and male patients were associated with non-significant reduced likelihood
291 of long COVID. Similarly, order age groups and presence of newly diagnosed medical conditions were
292 associated with non-significant, however increased, odds of long COVID.

293 **Discussion**

294 Long COVID symptoms were common among patients presenting for care in specialized post-acute
295 COVID-19 clinics in Zambia, which could represent potential substantial morbidity from COVID-19.
296 Factors associated with long COVID in Zambia included severe COVID-19, hospital length of stay and
297 presence of pre-existing comorbidities. Hospitalization was not significantly associated with long COVID
298 while patients with limitations in daily activities that may have impacted on the patients' functional
299 status were independently associated with long COVID. Longitudinally vaccination patients had
300 indistinguishable likelihood of long COVID and so was sex and age.

301 A severe form of COVID-19 is known to increase the risk of an intense immune response that could lead
302 to widespread inflammation [50]. The inflammatory response can persist post-acute infection and could
303 have led to the immune system being dysregulated, leading to prolonged persistent symptoms and
304 complications of COVID-19 in the patients. This could have led to observed association of severe COVID-
305 19 long COVID as has been reported in other studies [35, 36, 51, 52].

306 Patients with longer hospital stays may have received intensive medical interventions and additional
307 treatments. This could have potentially affected the immune response and the body's ability to recover
308 from the acute COVID-19p, which in turn may have increased the likelihood of long COVID. Furthermore,

309 patients with pre-existing comorbidities may have been more susceptible to severe COVID-19 and may
310 have been at higher risk of developing long COVID. This is consistent with what is reported by other
311 studies on patients with longer hospitalization stay for acute COVID-19 or pre-existing comorbidities and
312 their association to long COVID [52-54].

313 Patients referred to specialist services may have had residual organ damage from acute COVID-19 which
314 may have required specialist care. This may have been closely related to the observed limitations in daily
315 activities that may have impacted on the patients' functional status since acute COVID-19 as have been
316 reported in a previous study [9]. Although this association was independently significant, we could not
317 adjust for it at multivariable analysis due to missingness that resulted in listwise deletion of more than
318 half the study sample. Furthermore, no feedback systems were in place to inform PAC-19 clinics of the
319 outcome of specialist care of referred patients.

320 COVID-19 vaccines have been shown to be effective at preventing symptomatic SARS-CoV-2 infections
321 and long COVID [55, 56]. In this study, however, vaccinated patients failed to show significant protective
322 association between COVID vaccination and long COVID. A possible explanation for this finding might be
323 the heterogeneity in vaccination status during the study since Zambia only began offering COVID-19
324 vaccination in April 2021 (i.e., right before the delta wave and ~8 months after patients began
325 presenting for care in PAC-19 clinics) [57]. For example, among the patients diagnosed with SARS-CoV-2
326 during the wild type and beta dominant variants periods, prior to publicly available COVID-19
327 vaccination in Zambia, only 1 patient ever reported being vaccinated.

328 Unlike pre-existing comorbidities, newly diagnosed medical conditions had a non-significant association
329 with long COVID. Newly diagnosed medical conditions in COVID-19 patients may have been as a result of
330 multiorgan effects or autoimmune conditions [3]. Fewer patients, overall, had newly diagnosed medical
331 conditions which could explain the non-significant association. Sex and age were similarly not
332 associated with long COVID which seem to suggest that factors associated with long COVID in Zambia
333 were largely clinical as opposed to demographic.

334 With regards to recovery time from long COVID, most patients with long COVID had symptom resolution
335 by the second month of follow up. Overall, we found that commonly reported long COVID symptoms in
336 Zambia were similar to findings in other studies [35, 36, 38, 52]. However, symptoms like forgetfulness
337 (commonly reported among long COVID patients) and change in sleep were less commonly reported in
338 our study compared to previous reports [17, 20].

339 In both the cross-sectional and longitudinal analysis, inpatients compared to outpatient care during
340 COVID-19 episode were found to be associated with indistinguishable likelihood of long COVID. One
341 reason for this might be that those who were outpatient and attending PAC-19 clinics were a special
342 subset of outpatients with COVID-19 (i.e., they were seeking out or were referred for follow-up care
343 during acute COVID-19e). Furthermore, inpatients (the majority of whom had severe COVID-19) might
344 have been more likely to be referred to PAC-19 clinic whereas those who were outpatient were likely
345 self-referral to PAC-19 clinic meaning only those who really needed it (i.e., those with ongoing
346 symptoms) were in this study.

347 The findings in this study are subject to several limitations. Firstly, only patients attending PAC-19 clinics
348 were included in the study, so other patients with long COVID who sought care elsewhere (or didn't seek
349 care) were not included. This potentially represents some form of selection bias within the study since
350 other long COVID patients could have by-passed the PAC-19 clinic and presented directly to clinicians or
351 specialist service at outpatient departments. Furthermore, PAC-19 clinics took time to scale-up
352 throughout Zambia and some persons might still have faced difficulty accessing them. Overall, fewer
353 than 1% of the over 344,000 confirmed COVID-19 cases in Zambia as of January 2023 presented for care
354 in PAC-19 clinics.

355 Secondly, COVID-19 illness history (i.e., date of SARS-CoV-2 testing, hospitalization status, vaccination
356 history, acute COVID-19 episode details, etc.) were self-reported by patients to clinicians which cannot
357 rule out self-serving bias. Thirdly, the study utilized routinely collected clinical information from PAC-19
358 clinics which had substantial missingness for some key variables such as vaccination status and referral
359 to specialist services. Thus, these variables were not adjusted for at multivariable analyses so as to
360 maintain sample size. And lastly, patients were not retested for SAR-CoV-2 infection at subsequent
361 PAC-19 review visits and so the possibility of reinfection could not be ruled out.

362 **Conclusion**

363 Given the burden of COVID-19 in Zambia, the findings of a potentially substantial morbidity due to long
364 COVID, and that yet few patients overall with COVID-19 had attended a PAC-19 clinic, scaling up PAC-19
365 care services and integrating into routine clinical care could improve access by patients and further aid
366 in understanding the true burden of long COVID in Zambia. This could be coupled with efforts to expand
367 knowledge of long COVD among clinicians and the general population in Zambia. Scaling of vaccination,
368 may likely, provide better outcomes not only for long COVID but also during acute SARS-CoV-2 infection.
369 Improving data quality for routine clinical data, could possibly be achieved by utilizing the existing

electronic health record in Zambia (SmartCare) for all clinical encounters. Information sharing between referral care services and PAC-19 clinics could aid in understanding the outcome of long COVID among patients requiring specialist care.

Disclaimer: *The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention (CDC) or the study funders.*

Supporting information

S1 Fig: Histogram of longitudinal PAC-19 clinic attendance (all visits) by time since COVID-19 diagnosis, August 2020 January 2023

S1 Table: Frequencies of pre-existing and newly diagnosed comorbidities of PAC-19 Clinic Patients in Zambia, Aug. 2020–Jan. 2023

S2 Table: Factors associated with long COVID at first visit to PAC-19 clinic among acute COVID-19 inpatients and outpatients in Zambia, August 2020 – January 2023 (N=1,359)

S3 Table: Longitudinal Demographic and Clinical Characteristics of PAC-19 Clinic Patients in Zambia, Aug. 2020–Jan. 2023

S4 Table: Longitudinal risk factors and association for long COVID among acute COVID-19 hospitalized and non-hospitalized patients in Zambia, August 2020 – January 2023 (N=548)

References

1. WHO. *International Health Regulations Emergency Committee on novel coronavirus in China*. 2020 [cited 2022 12 May]; Available from: https://www.who.int/news-room/events/detail/2020/01/30/default-calendar/international-health-regulations-emergency-committee-on-novel-coronavirus-in-china.
2. WHO. *WHO Coronavirus (COVID-19) Dashboard*. 2023 [cited 2022 16 October]; Available from: https://covid19.who.int/.
3. Raveendran, A.V., R. Jayadevan, and S. Sashidharan, *Long COVID: An overview.* Diabetes Metab Syndr, 2021. **15**(3): p. 869-875.
4. Klok, F.A., et al., *The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19.* European Respiratory Journal, 2020. **56**(1): p. 2001494.

5. Peghin, M., et al., *Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients.* Clin Microbiol Infect, 2021. **27**(10): p. 1507-1513.
6. Soriano, J.B., et al., *A clinical case definition of post-COVID-19 condition by a Delphi consensus.* Lancet Infect Dis, 2022. **22**(4): p. e102-e107.
7. Venturelli, S., et al., *Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation.* Epidemiology and Infections, 2021. **149**: p. e32.
8. Ahmed, H., et al., *Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis.* Journal of Rehabil itation of Medicine, 2020. **52**(5): p. jrm00063.
9. Hui, D.S., et al., *Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors.* Thorax, 2005. **60**(5): p. 401-9.
10. Lam, M.H., et al., *Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up.* JAMA Internal Medicine, 2009. **169**(22): p. 2142-7.
11. Lee, S.H., et al., *Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors.* Psychiatry Investigation, 2019. **16**(1): p. 59-64.
12. Thaweethai, T., et al., *Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.* JAMA, 2023. **329**(22): p. 1934-1946.
13. Vahey, G.M., et al., *Symptom Profiles and Progression in Hospitalized and Nonhospitalized Patients with Coronavirus Disease, Colorado, USA, 2020.* Emerg Infect Dis, 2021. **27**(2): p. 385-395.
14. Nalbandian, A., et al., *Post-acute COVID-19 syndrome.* Nature Medicine, 2021. **27**(4): p. 601-615.
15. Chippa, V., A. Aleem, and F. Anjum, *Post Acute Coronavirus (COVID-19) Syndrome*. 2021: StatPearls Publishing, Treasure Island (FL).
16. Danesh, V., et al., *Symptom Clusters Seen in Adult COVID-19 Recovery Clinic Care Seekers.* J Gen Intern Med, 2023. **38**(2): p. 442-449.
17. Davis, H.E., et al., *Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.* EClinicalMedicine, 2021. **38**: p. 101019.
18. WHO. *Post COVID-19 condition (Long COVID)*. 2022 [cited 2023 6 July]; Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition.
19. Carfì, A., R. Bernabei, and F. Landi, *Persistent Symptoms in Patients After Acute COVID-19.* JAMA, 2020. **324**(6): p. 603-605.
20. Huang, C., et al., *6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.* Lancet, 2021. **397**(10270): p. 220-232.
21. Tenforde, M.W., et al., *Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020.* MMWR Morb Mortal Wkly Rep, 2020. **69**(30): p. 993-998.
22. Ballering, A.V., et al., *Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study.* Lancet, 2022. **400**(10350): p. 452-461.
23. Ayoubkhani, D., et al., *Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-Based, Matched Cohort Study.* Open Forum Infect Dis, 2022. **9**(9): p. ofac464.
24. Bull-Otterson, L., et al., *Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021.* MMWR Morb Mortal Wkly Rep, 2022. **71**(21): p. 713-7.
25. Ceban, F., et al., *Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis.* Brain Behav Immun, 2022. **101**: p. 93-135.

26. Xu, E., Y. Xie, and Z. Al-Aly, *Long-term neurologic outcomes of COVID-19.* Nat Med, 2022. **28**(11): p. 2406-2415.
27. Davis, H.E., et al., *Long COVID: major findings, mechanisms and recommendations.* Nature Reviews Microbiology, 2023.
28. Nyasulu, P.S., J.L. Tamuzi, and R.T. Erasmus, *Burden, causation, and particularities of Long COVID in African populations: A rapid systematic review.* IJID Regions, 2023. **8**: p. 137-144.
29. Antonelli, M., et al., *Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.* Lancet Infect Dis, 2022. **22**(1): p. 43-55.
30. Morello, R., et al., *Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study.* eClinicalMedicine, 2023. **59**: p. 101961.
31. Tsampasian, V., et al., *Risk Factors Associated With Post−COVID-19 Condition: A Systematic Review and Meta-analysis.* JAMA Internal Medicine, 2023. **183**(6): p. 566-580.
32. Frallonardo, L., et al., *Incidence and burden of long COVID in Africa: a systematic review and meta-analysis.* Scientific Reports, 2023. **13**(1): p. 21482.
33. Osikomaiya, B., et al., *'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria.* BMC Infectious Diseases, 2021. **21**(1): p. 304.
34. Müller, S.A., et al., *Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review.* Lancet Glob Health, 2023. **11**(11): p. e1713-e1724.
35. Osikomaiya, B., et al., *'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria.* BMC Infect Dis, 2021. **21**(1): p. 304.
36. Dryden, M., et al., *Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study.* Lancet Glob Health, 2022. **10**(9): p. e1247-e1256.
37. Moyo, E., et al., *Risk factors and clinical presentations of long COVID in Africa: A scoping review.* Journal of Infection and Public Health, 2023. **16**(12): p. 1982-1988.
38. Zulu, J.E., et al., *Two-month follow-up of persons with SARS-CoV-2 infection-Zambia, September 2020: a cohort study.* Pan Afr Med J, 2022. **41**: p. 26.
39. Mulenga, L.B., et al., *Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey.* Lancet Glob Health, 2021. **9**(6): p. e773-e781.
40. Sheppard, R.J., et al., *Using mortuary and burial data to place COVID-19 in Lusaka, Zambia within a global context.* Nat Commun, 2023. **14**(1): p. 3840.
41. Gill, C.J., et al., *What is the prevalence of COVID-19 detection by PCR among deceased individuals in Lusaka, Zambia? A postmortem surveillance study.* BMJ Open, 2022. **12**(12): p. e066763.
42. Heilmann, E., et al., *SARS-COV-2 seroprevalence trend among pregnant women in Zambia, 2021-2022*, in *Conference on Retroviruses and Opportunistic Infections (CROI)*. 2023: Seattle, Washington.
43. Mumba, T.K., et al., *Seroprevalence survey of SARS-CoV-2, community behaviors, and practices in Kansanshi and Kalumbila mining towns.* Frontiers in Public Health, 2023. **11**.
44. Shanaube, K., et al., *SARS-CoV-2 seroprevalence and associated risk factors in periurban Zambia: a population-based study.* Int J Infect Dis, 2022. **118**: p. 256-263.
45. Lewis, H.C., et al., *SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021.* BMJ Glob Health, 2022. **7**(8).
46. Ministry of Health (Zambia). *Clinical Guidance for Management of Patients with Coronavirus Disease 2019 (COVID-19)*. 2020 [cited 2023 12 August]; Available from: https://www.moh.gov.zm/?wpfb_dl=181.

47. Ministry of Health, *Clinical and Operational Guidelines for the Management of Post-Acute Covid-19 (PAC-19) Patients in Zambia*, in *Post-Acute COVID-19 Clinical and Operational Guidelines*. 2022, Ministry of Health (Zambia): Lusaka.
48. GISAID. *EpiCov*. 2023 [cited 2023 12 August]; Available from: https://www.epicov.org/epi3/frontend#24d000.
49. Charan, J. and T. Biswas, *How to calculate sample size for different study designs in medical research?* Indian J Psychol Med, 2013. **35**(2): p. 121-6.
50. Wong, R.S.Y., *Inflammation in COVID-19: from pathogenesis to treatment.* Int J Clin Exp Pathol, 2021. **14**(7): p. 831-844.
51. Zhang, H.P., et al., *Recent developments in the immunopathology of COVID-19.* Allergy, 2023. **78**(2): p. 369-388.
52. Fernández-de-las-Peñas, C., et al., *Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis.* European Journal of Internal Medicine, 2021. **92**: p. 55-70.
53. Cirulli, E.T., et al., *Long-term COVID-19 symptoms in a large unselected population.* medRxiv, 2020: p. 2020.10.07.20208702.
54. Asadi-Pooya, A.A., et al., *Risk Factors Associated with Long COVID Syndrome: A Retrospective Study.* Iran J Med Sci, 2021. **46**(6): p. 428-436.
55. Rane, M.S., et al., *Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.* Vaccine, 2023. **41**(4): p. 989-998.
56. Britton, A., et al., *Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance.* Jama, 2022. **327**(11): p. 1032-1041.
57. Chanda, D., et al., *COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021-2022.* Open Forum Infect Dis, 2022. **9**(9): p. ofac469.